0001261249 false 0001261249 2022-08-22 2022-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549










Pursuant to Section 13 or 15(D)

of the Securities Exchange Act of 1934


August 22, 2022

Date of report (Date of earliest event reported)




Agile Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Delaware 001-36464 23-2936302
(State or other jurisdiction
of incorporation)


File Number)

(IRS Employer

Identification No.)


500 College Road East, Suite 310

Princeton, New Jersey

(Address of principal executive offices)



(Zip Code)


Registrant's telephone number, including area code (609) 683-1880

(Former name or former address, if changed since last report)  




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share AGRX The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 8.01. Other Events.


On August 22, 2022, the Board of Directors (the “Board”) of Agile Therapeutics, Inc. (the “Company”) authorized the increase of the existing at the market offering program (the “At the Market Offering Program”) for which H.C. Wainwright & Co., LLC acts as agent (the “Agent”). As increased, the Company may now offer and sell, from time to time through the Agent, shares of the Company’s common stock having an aggregate offering price of up to $75.0 million. The Company has filed with the Securities and Exchange Commission a prospectus supplement, dated August 23, 2022, to describe the increase, which supersedes and replaces the April 27, 2022 prospectus supplement.


The opinion of Morgan, Lewis & Bockius LLP, the Company’s counsel, regarding the validity of the shares of the Company’s common stock that will be issued pursuant to the At the Market Offering Program is filed herewith as Exhibit 5.1.


This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of shares of Common Stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.


Item 9.01.     Financial Statements and Exhibits.


(d)           Exhibits.


5.1   Opinion of Morgan, Lewis & Bockius LLP
23.1   Consent of Morgan, Lewis & Bockius LLP (contained in Exhibit 5.1)
104   Cover Page Interactive Data File (Embedded within the Inline XBRL Document).







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Agile Therapeutics, Inc.
Dated: August 24, 2022 By: /s/ Alfred Altomari
  Name: Alfred Altomari
  Title: President and Chief Executive Officer





Exhibit 5.1


August 24, 2022


Agile Therapeutics, Inc.

500 College Road East, Suite 310

Princeton, NJ 08540


RE: Agile Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-249273)


Ladies and Gentlemen:


We have acted as counsel to Agile Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale by the Company from time to time of shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $75 million (the “Placement Shares”), pursuant to the Registration Statement on Form S-3 (File No. 333-249273), filed with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Act”), on October 2, 2020, which was declared effective by the SEC on October 14, 2020 (the “Registration Statement”), the related base prospectus, dated October 14, 2020 (the “Base Prospectus”), and the prospectus supplement, dated August 23, 2022 (the “Prospectus Supplement” and together with the Base Prospectus, the “Prospectus”), filed with the SEC pursuant to Rule 424(b) under the Act, and the Common Stock Sales Agreement, dated April 27, 2022, by and between the Company and H.C. Wainwright & Co., LLC, as sales agent (the “Sales Agreement”).


In connection with this opinion letter, we have examined the Registration Statement, the Prospectus, the Sales Agreement, and originals, or copies certified or otherwise identified to our satisfaction, of the Amended and Restated Certificate of Incorporation, as amended, and the Amended and Restated Bylaws of the Company, and such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein.


We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile or photostatic copies and the authenticity of the originals of all documents submitted to us as copies.


Based upon the foregoing, we are of the opinion that the Placement Shares have been duly authorized by the Company and, when issued and sold by the Company and delivered by the Company against receipt of the purchase price therefor, in the manner contemplated by the Sales Agreement, will be validly issued, fully paid and non-assessable.


The opinions expressed herein are limited to Delaware General Corporation Law.


We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the prospectus included in the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the SEC thereunder.


Very truly yours,